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Abstract: (1) Background: To evaluate the efficacy at 6 years postoperative after the implantation of 
a trifocal intraocular lens (IOL) AT Lisa Tri 839MP. The secondary objective was to evaluate the 
contrast sensitivity defocus curve (CSDC), light distortion analysis (LDA), and patient reported out-
comes (PROs). (2) Methods: Sixty-two subjects participated in phone call interviews to collect data 
regarding a visual function questionnaire (VF-14), a patient reported spectacle independence ques-
tionnaire (PRSIQ), and questions related to satisfaction and decision to be implanted with the same 
IOL. Thirty-seven of these subjects were consecutively invited to a study visit for measurement of 
their visual acuity (VA), CSDC, and LDA. (3) Results: The mean monocular distance corrected VA 
was −0.05, 0.08, and 0.05 logMAR at far and distances of 67 cm and 40 cm, respectively. These VAs 
were significantly superior to those reported in previous literature (p < 0.05). The total area under 
the CSDC was 2.29 logCS/m−1 and the light distortion index 18.82%. The mean VF-14 score was 
94.73, with 19.4% of subjects requiring spectacles occasionally for near distances, and 88.9% consid-
ering the decision of being operated again; (4) Conclusions: Long-term AT LISA Tri 839MP IOL 
efficacy results were equal or better than those reported 12 months postoperatively in previous 
studies. The spectacle independence and satisfaction rates were comparable to those reported in 
short-term studies. 
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1. Introduction 
The intraocular lens (IOL) AT LISA tri 839MP (henceforth referred to as 839MP; Carl 
Zeiss Meditec AG, Germany) was, together with the FineVision (Physiol S.A., Liege, Bel-
gium), the first trifocal IOL that received the CE mark in 2012 and 2010, respectively [1]. 
The short-term safety and efficacy of 839MP has been widely reported (1 to 6 month fol-
low-up) [2–4]. Long-term studies with 839MP are commonly referred to as those that in-
volve 1 or 2 year follow-up periods [5–9]. To the best of our knowledge, there is only one 
retrospective study evaluating a longer period of 3–4 years follow-up, in which only Nd-
YAG rates were analyzed [10]. The 839MP IOL remains one of the most popular and fre-
quently implanted multifocal IOL (MIOL), and thus, the results for longer periods are 
considered to be of great interest. The main aim of this study was to evaluate the efficacy 
6 years after binocular implantation of the 839MP IOL. The secondary aim was to evaluate 
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the contrast sensitivity defocus curves, light distortion analysis, and patient reported out-
comes (PROs) in eyes implanted with this modality of trifocal IOL. 
2. Materials and Methods 
This retrospective and cross-sectional study was designed to be conducted during 
the COVID-19 pandemic period, following the recommendations of the European Medi-
cines Agency [11]. To minimize the pandemic risks, the study consisted of two stages, 
namely: (1) PRO evaluations through a phone call for all of the patients implanted with 
839MP IOL from March 2014 to June 2015, who met the inclusion/exclusion criteria, and 
(2) a visit to our center for visual performance measurements by the patients who were 
consequently selected during the phone call interviews. The study was approved by the 
Ethics Committee of Research, Almería Center, Torrecardenas Hospital Complex (QV-20-
02), and was performed in accordance with the tenets of the Declaration of Helsinki. Oral 
consent was provided in stage 1 during the phone call, and the signed consent was pro-
vided in stage 2. The study was registered at ClinicalTrials.gov (registration number: 
NCT04861909). 
2.1. Subjects 
Ninety-two patients that underwent refractive lens exchange or cataract surgery 
were identified in our historical database to be contacted via phone for the assessment of 
long-term PROs (first stage). The inclusion criteria for this first stage were patients older 
than 45 years old at the time of surgery and younger than 80 years old at the time of the 
phone call interview; patients who had undergone surgery in the first eye at least 78 
months prior to the interview, and 66 months at least in the second eye; and no reports of 
surgical complications recorded in the clinical history that could deteriorate visual acuity. 
The exclusion criteria were any ocular disease reported in the clinical history leading to a 
visual acuity loss, such as recurrent anterior segment diseases and retinal and optic nerve 
alterations, and any ocular surgery, including corneal laser refractive surgery, prior or 
after the surgery. A total of 77 patients who met the mentioned inclusion and exclusion 
criteria after reviewing the clinical history were attempted to be contacted by phone. How-
ever, only 62 subjects were successfully contacted, interviewed, and consecutively invited 
to visit our centre for a vision assessment to achieve the required sample size for the sec-
ond stage (n = 37). Exclusion criteria for completing the vision assessment in the second 
stage were posterior capsular opacification (PCO) grade density ≥2 according to surgeon 
criteria that induced a visual loss in corrected distance visual acuity (CDVA) ≥ 0.2 logMAR 
and irregular corneal astigmatism at 4 mm above 0.5 µm measured with Pentacam HR 
(Oculus Optikgeräte GmbH, Wetzlar, Germany). 
2.2. Clinical Procedures 
The PROs collected during the phone call interview were the Spanish validated Vis-
ual Function Questionnaire (VF-14) without spectacles [12,13]; a non-validated Spanish 
translation of the English validated patient reported spectacle independence question-
naire (PRSIQ) [14]; and three independent questions about satisfaction with vision, the 
level of disturbance related to photic phenomena, and the decision of whether the patient 
would choose to be implanted again with the same MIOL, considering their vision with-
out any spectacle correction. 
Patients conducting the visual performance assessment visit underwent a slit-lamp 
and medical exploration for adverse event detection [15], including PCO density grading 
from 0 to 4 in the eyes without a previous Nd-YAG capsulotomy and anterior capsular 
opacification [16,17]. The best spectacle refraction was obtained at 4 m (−0.25 D added for 
correction to infinity) and monocular visual acuities, uncorrected and distance corrected, 
were obtained at far, intermediate (67 cm), and near vision (40 cm) using an iPad ETDRS 
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chart (VisionC 2.0; https://www.test-eye.com/en/apps-for-eye-care-research/visionc; Ac-
cessed 5 May 2021, Spain) [15]. Binocular uncorrected visual acuities were also measured 
at the three distances mentioned. Standard notation was used for abbreviating the visual 
acuities [18]. 
An eye randomization (RandomIZE: Randomization Tool, IOS App) was performed, 
selecting only the right or left eye for some of the tests requiring longer testing times, as 
described below. Some retrospective data and biometric eye parameters described in Ta-
ble 1 were also obtained for the eye randomly selected with the Pentacam AXL (Oculus 
Optikgeräte, Wetzlar, Germany), IOL Master 500 (Carl Zeiss Meditec AG, Jena, Germany), 
and Keratograph 5M systems (Oculus Optikgeräte, Wetzlar, Germany).  
The same iPad was used to measure the contrast sensitivity defocus curve (CSDC) 
with a Multifocal Lens Analyzer (3.0; Snellen letters; https://www.defocuscurve.com/en/; 
Accessed 5 May 2021) [19,20]. Defocus lenses from +1.00 D to −4.00 D, in steps of +0.50 D, 
were selected for measuring CSDC at 4 m in the randomly selected eye, with a best dis-
tance spectacle refraction and vergence distance correction of +0.25 D. The Light Distor-
tion Analyzer (CEORLab, University of Minho, Braga, Portugal) was used to measure the 
photic phenomena monocularly, with the best distance correction in the eye randomly 
selected and binocularly without correction 2 m from the observer (proximal vergence 
corrected with +0.50 D). The following three variables were obtained: the light distortion 
index (LDI, %), the best fit circle irregularity (BFCi, mm), and the best fit circle radius 
(BFCr, mm) [5]. 
2.3. Surgery and Intraocular Lens 
All cataract surgeries were performed by the same surgeon (JF) by phacoemulsifica-
tion, either assisted or not assisted by a femtosecond laser, at Qvision (Ophthalmology 
Department, Vithas Virgen del Mar Hospital). Temporal clear corneal incisions were con-
ducted during surgery in all cases with the insertion of the IOLs at 0–180° location. The 
839 MP was the trifocal IOL implanted in all cases, which has been widely described in 
previous peer-reviewed literature [1,21]. 
2.4. Statistical Analysis 
The primary end-points were the uncorrected and corrected monocular visual acui-
ties at far, intermediate, and near distances. Secondary end-points were contrast sensitiv-
ity defocus curves, light distortion analysis, and patient reported outcomes. Only the ran-
domized eye was considered for the inferential statistics analysis. In a non-inferiority de-
sign, with one sided testing, the null hypothesis of the mean differences equal or higher 
to the 12-month means reported by Mojzis et al. [6] for primary end-points plus a margin 
of 0.1 logMAR was planned before the study. The sample size was computed with the 
software G*Power (version 3.1; https://www.gpower.hhu.de/; Accessed 5 May 2021), con-
sidering the mean differences of 0.1 logMAR and the standard deviations reported by 
Mojzis et al. [6]. The sample size of 37 subjects was selected considering a type I error 
probability of 0.05 and a statistical power of 0.99 for the primary end-point. Normal dis-
tributions were tested with the Shapiro–Wilk test, and the Wilcoxon-signed rank test for 
one sample was selected for testing the hypothesis for median differences because of the 
non-normal distribution of variables. Descriptive statistics are detailed in the results sec-
tion as mean ± standard deviation (median (interquartile range)). A survival analysis was 
performed for the assessment of the Nd:YAG rates. Correlations were assessed with 
Spearman rho, and associations between ordinal variables from the questionnaires were 
analyzed with Sommers’d. Likewise, a multiple linear regression analysis was performed 
to define the variables predicting the magnitude of LDI. The Refractive Analysis toolbox 
for MATLAB (R2019; MathWorks, Natick, MA, USA) was used for conducting the stand-
ard plots [22]. Shifted defocus curves were corrected before computing the descriptive 
statistics, and the areas under the defocus curve (AUCs) for total (T, +1 to −4 D), far (F, 
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+0.5 to −0.5 D), intermediate (I, −0.5 to −2 D), and near (N, −2 to −4 D) ranges were calcu-
lated. SPSS version 24 software (SPSS Inc., Chicago, IL, USA) was used for the statistical 
analysis. 
3. Results 
3.1. Recruited Subjects 
From the 92 subjects reviewed, 15 subjects were excluded for the following reasons: 
five had previous laser photorefractive keratectomy (PRK) interventions, four developed 
concomitant diseases, one had a surgical complication with a sulcus implant in one eye, 
two had additional surgical interventions during the follow-up, two cases reported of spo-
radic double vision, and one subject had a toric IOL implanted in one eye. Sixty-two sub-
jects were finally interviewed, 26 men and 36 women, with mean age of 60.74 ± 5.92 (60 
[9]) years old. From those subjects, a total of 37 consecutive patients, whose demographic 
variables are shown in Table 1, attended the study visit at our clinic—15 men and 22 
women. None of the 37 consecutive patients invited to the study visit had to be excluded 
for not accomplishing the inclusion/exclusion criteria defined in the protocol. 
Table 1. Demographic and biometric characteristics of the sample recruited for study visit (n = 37). 
 Mean ± SD Median [IQR] 
Age at follow-up visit 61.03 ± 5.47 61 [8.50] 
IOL Master 500   
Axial length (mm) 23.33 ± 1.14 23.15 [1.51] 
Mean corneal anterior keratometry (D) 43.70 ± 1.37 43.95 [1.64] 
Pentacam AXL   
Anterior lens position (mm)  4.49 ± 0.35 4.45 [0.39] 
Intraocular lens power (D) 21.41 ± 3.18 22 [4.50] 
Irregular astigmatism at 4 mm (µm) 0.15 ± 0.05 0.15 [0.09] 
Regular astigmatism (D) 0.49 ± 0.27 0.40 [0.45] 
Corneal spherical aberration for mesopic pupil size (µm) 0.17 ± 0.13 0.14 [0.18] 
Keratograph 5M   
Photopic pupil diameter (mm) 2.96 ± 0.49 2.90 [0.70] 
Mesopic pupil diameter (mm) 5.17 ± 0.85 5 [1.20] 
SD: Standard deviation; IQR: Interquartile range. 
3.2. Efficacy and Accuracy 
Monocular visual acuities for the randomized eyes are reported in Table 2. Signifi-
cantly better visual acuities values were obtained for all distances with and without dis-
tance correction when compared with the values reported in the literature for a 12-month 
follow-up plus the established margins, of either 0.1 or 0.02 logMAR. The mean binocular 
uncorrected visual acuities were 0.01 ± 0.09 logMAR for far, 0.02 ± 0.08 logMAR for inter-
mediate, and 0.04 ± 0.09 logMAR for near. The median and interquartile range for binoc-
ular uncorrected vision at the three distances was 0 and 0.1 logMAR, respectively. Figure 
1A–C shows the monocular efficacy standard plots. The mean postoperative spherical 
equivalent (SE) was −0.24 ± 0.34 D (−0.25 [0.50] D). Figure 1D shows the percentage of eyes 
(68.92%) with an SE within ±0.25 D and those with an SE within ± 0.50 D (93.24%). All eyes 
achieved a postoperative SE within ±1.00 D. All eyes showed a refractive cylinder below 
1.00 D for astigmatism (Figure 1E). 
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Table 2. Efficacy at 6-years for the random eye in comparison with that reported 12-months postoperatively in previous 
literature. 
 
6-Year Follow-up  
Mean ± SD  
Median [IQR] 
12-month Median from 
Literature 
z-Test, p-Value 
Margin of 0.1 logMAR 
z-Test, p-Value 
Margin of 0.02 logMAR 
UDVA 
0.06 ± 0.12 
0.1 [0.1] 
0.02 −1.75, 0.04 2.001, 0.023 
CDVA 
−0.05 ± 0.07 
−0.1 [0.1] 
0.02 −5.18, <0.0005 −4.53, <0.0005 
UIVA 
0.07 ± 0.09 
0.0 [0.1] 
0.12 −4.84, <0.0005 −3.31, <0.0005 
DCIVA 
0.08 ± 0.09 
0.1 [0.1] 
0.12 −4.85, <0.0005 −3.50, <0.0005 
UNVA 
0.08 ± 0.10 
0.1 [0.1] 
0.22 −5.33, <0.0005 −5.05, <0.0005 
DCNVA 
0.05 ± 0.06 
0 [0.1] 
0.22 −5.44, <0.0005 −5.44, <0.0005 
UDVA—uncorrected distance visual acuity; CDVA—corrected distance visual acuity; UIVA—uncorrected intermediate 
visual acuity; DCIVA—distance corrected intermediate visual acuity; UNVA—uncorrected near visual acuity; DCNVA—
distance corrected near visual acuity. 




Figure 1. Efficacy plot for (A) far, (B) intermediate, and (C) near distances showing the cumulated percentage of eyes 
achieving a particular level of uncorrected and corrected visual acuity postoperatively. Percentage of eyes achieving (D) 
a postoperative sphere equivalent non-relative to the intended target and (E) a postoperative cylinder refraction. (F) Mean 
monocular contrast sensitivity defocus curve with 95% confidence interval in error bars and with areas under the curve 
(AUCs) for total (T), far (F), intermediate (I), and near ranges (N). 
3.3. Contrast Sensitivity Defocus Curve and Light Distortion 
The mean monocular contrast sensitivity defocus curve with a 95% confidence inter-
val is shown in Figure 1F. From the biometric eye parameters measured and summarized 
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in Table 1, only corneal spherical aberration for the mesopic pupil size was significantly 
related with the AUCs (T, rho = −0.44, p = 0.007; F, rho = −0.4, p = 0.01; I, rho = −0.42, p = 
0.009; N, rho = −0.38, p = 0.02). 
LDI was 18.82 ± 7.25% (19.42 (11.34)) for monocular vision and 15.64 ± 8.41% (14.64 
(10.39)) for binocular vision. BFCr was 34.79 ± 6.89 (36 (11.30)) mm for monocular vision 
and 30.98 ± 6.35 (31.30 (11.35)) mm for binocular vision. Finally, BFCi was 0.44 ± 0.38 mm 
(0.37 (0.43)) for monocular vision and 0.45 ± 0.35 mm (0.43 [0.45]) for binocular vision. LDI 
was significantly correlated with spherical equivalent residual refraction, spherical aber-
ration at mesopic pupil size, and the total area under the contrast sensitivity defocus 
curve. A multiple linear regression model significantly predicted the light distortion index 
with the sequential addition of SE (R2 = 0.19), TAUC (R2 = 0.37), and SA (R2 = 0.46) as 
prediction variables. 
3.4. Patient Reported Outcomes 
Figure 2A shows the results of the VF-14 questionnaire. All of the questions were 
answered except for two subjects who did not answer the questions related to driving as 
they did not drive. No difficulty was found in more than 85% of subjects for all of the 
tasks, except for small print reading and driving at night. The total score was 94.73 ± 6.8 
(96.43 (4.46)). Table 3 shows the results for the PRSIQ and for the additional questions.  
Table 3. Descriptive results for the patient reported spectacle independence questionnaire (PRSIQ) and the additional 
questions. Centrality and variation indices are in the first column and percentage of answers for each category (frequency) 
are in the Cat. columns. 
PRSIQ Mean ± SD; Median [IQR] Cat. 1 Cat. 2 Cat. 3 Cat. 4 Cat. 5 
Need Glasses       
Distance 2 ± 0; 2 [0] 0 100    
Intermediate 2 ± 0; 2 [0] 0 100    
Near 1.81 ± 0.40; 2 [0] 19.4 80.6    
Often wear       
Distance 5 ± 0; 5 [0] 0 0 0 0 100 
Intermediate 5 ± 0; 5 [0] 0 0 0 0 100 
Near 4.74 ± 0.57; 5 [0] 0 0 6.5 12.9 80.6 
Comfortably without wear       
Distance 1.06 ± 0.36; 1 [0] 96.8 0 3.2 0 0 
Intermediate 1.06 ± 0.36; 1 [0] 96.8 0 3.2 0 0 
Near 1.37 ± 0.83; 1 [0] 77.4 16.1 6.5 0 0 
Coding: “Yes” (Category 1) and “No” (Category 2). Wear and function items used verbal response labels of “all of the time” (Cate-
gory 1), “most of the time” (Category 2), “Some of the time” (Category 3), “A little of the time” (Category 4), and “None of the 
time” (Category 5). 
Additional Questions (X)       
Satisfaction (satisfied)       
Distance 4.63 ± 0.75; 5 [1] 0 4.8 1.6 19.4 74.2 
Intermediate 4.56 ± 0.88; 5 [1] 1.6 4.8 1.6 19.4 72.6 
Near 4.50 ± 0.88; 5 [1] 0 8.1 1.6 22.6 67.7 
Photic phenomena (bothersome) 2.21 ± 1.29; 2 [1] 32.3 45.2 3.2 8.1 11.3 
Operated again (likely) 4.53 ± 0.95; 5 [1] 1.6 6.5 3.2 14.5 74.2 
Coding for main words (X = satisfied or bothersome or likely): ‘‘not at all X” (Cat. 1), ‘‘slightly X” (Cat. 2), “neutral” (Cat. 3), ‘‘X” 
(Cat. 4), and ‘‘very X” (Cat. 5). 




Figure 2. (A) Percentage of subjects cumulated for each answer of the VF-14 questionnaire (n = 62). (B) Survival plot for 
Nd:YAG rates. 
No significant correlations of any of the light distortion analysis variables were found 
for either of the questions related to visual function during night vision driving or dis-
turbances of photic phenomena during night vision (p > 0.05). Significant associations 
were found between the decision to be implanted with the same MIOL and satisfaction 
with vision at far (d = 0.38, p = 0.01), intermediate (d = 0.51, p = 0.001), and near distance 
(d = 0.40, p = 0.002), but not with photic phenomena disturbances (d = −0.11, p = 0.25). 
3.5. Safety 
No secondary surgeries were required. No other adverse events beyond those de-
scribed in the previous recruitment section were identified either during the interview or 
in the study visit. 
From the 62 patients interviewed, 89 (71.77%) eyes required Nd:YAG (Alcon YAG 
laser 3000 LE Nd) capsulotomy during the 6-year follow-up. A total of 11 (17.7%) subjects 
did not require Nd-YAG capsulotomy in any of both eyes, whereas 13 subjects (21%) re-
quired this procedure in one eye and 38 (61.3%) in both eyes. A stratified analysis was 
conducted for the 37 subjects attending the study visit. According to this, 55 eyes (74%) 
from 31 subjects (84%) needed Nd:YAG capsulotomy during the 6-year follow-up as sur-
geon criteria, due to a decrease in visual performance. From the 19 eyes (26%) without 
previous Nd:YAG capsulotomy, nine (12%) were classified as zero level of PCO density, 
whereas eight (11%) and two (3%) were classified as grades 1 and 2, respectively. Non-
significant differences were obtained between the survival analysis from the call interview 
data and from the stratified analysis (p > 0.05); therefore, the data obtained in the study 
visit was used for a better interpretation (Figure 2B). The median time to require Nd:YAG 
capsulotomy obtained from the survival plot was 45 months (95% CI, 41.56 to 48.44 
months). The mean time for the described procedure was 43.97 ± 48.27 months. The ante-
rior capsular opacification was graded as zero for 72 eyes (97%) and as grade 1 for 2 the 
eyes of 2 subjects (3%). 
4. Discussion 
Although long-term studies with follow-up periods above 5 years have been re-
ported in the past for some bifocal intraocular lenses [23,24], there are no long-term stud-
ies reported to date with such a long follow-up period for trifocal MIOLs. The main aim 
of this study was to report the efficacy results of a selection of interviewed subjects im-
planted with a specific model of diffractive trifocal IOL in our center from March 2014 to 
June 2015 (6-year follow-up). For this purpose, patient reported outcomes were collected 
for all patients who were able to be contacted by a phone call interview, and patients were 
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consecutively invited for a visual performance assessment to our center, including the use 
of new metrics, such as contrast sensitivity defocus curves and light distortion analysis. 
The efficacy results in the 37 eyes of the study evaluated showed non-inferiority in 
comparison with the previously reported 12-month results [6]. Indeed, the results of the 
present study were better than those reported by Mojzis et al. [6] for all efficacy variables, 
except for UDVA. The reason for the superiority of our outcomes in comparison with Mo-
jzis et al. [6] may be that their sample at 12 months after surgery showed higher PCO rates 
with a lower number of Nd:YAG capsulotomies performed (3% in the present study with 
significant PCO during time of exploration versus the 15.8% reported in Mojzis et al. [6] 
study). Certainly, the efficacy results of the current series were more consistent with those 
reported in studies with shorter periods of time. A mean 6-year postoperative CDVA of 
−0.05 logMAR was found in the current study, which is a similar value compared to those 
reported in other studies at 3 and 6 months after implantation of the 839MP IOL (between 
−0.01 and −0.05 logMAR) [3,25,26]. The mean DCIVA in the present study was 0.08 log-
MAR, which is similar to the mean values of 0.06 logMAR and 0.07 logMAR reported for 
3- and 6-month follow-ups [3,25,26]. Similarly, the mean DCNVA was 0.05 logMAR, 
which is similar to the mean values of 0.07 logMAR and 0.06 logMAR also reported for 
the 3- and 6-month follow-ups [25,26].  
Some new metrics were also included in the current study. Particularly, CSDC has 
not been reported for short periods of time with the 839 MP IOL. Comparing the perfor-
mance for 0 D defocus location, the point that usually shows less difference in MTF be-
tween trifocal IOLs [27], the level slightly above 0.8 logCS found for a background bright-
ness of 85 cd/m2 in the current series was very close to the mean of 0.83 logCS obtained 
with several MIOLs for a background brightness of 250 cd/m2 [28]. This suggest that not 
only visual acuity remains stable 6 years after surgery, but also probably contrast sensi-
tivity.  
Another new metric that has been already measured with the 839MP IOL, but in short 
term periods, is the level of light distortion. Brito et al. [5] reported a monocular LDI, BFCr, 
and BFCi of 46.97%, 55.28 mm, and 5.71 mm, respectively. The results in the current series 
were considerably lower, with means of 18.82%, 34.79 mm, and 0.44 mm, respectively, for 
the same variables. According to this, it can be hypothesized that light distortion decreases 
with time, but it seems difficult to believe that the long-term results with the 839MP IOL 
could be lower than the short-term data reported by Brito et al. [5] with a monofocal IOL 
(i.e., 23.94% for the LDI). More studies are needed to confirm if this potential trend in a 
reduction in light distortion parameters may be related to neuroadaptation, considering 
that some changes in brain visual processing have been found to be associated to neu-
roadaptation to multifocality [29]. LDI was also related to some other biometric parame-
ters, decreasing with the increase of the spherical equivalent and with the increase of the 
total area under the CSDC. LDI was measured with best correction at infinity with addi-
tion of a +0.50 D lens; therefore, this increase in LDI can be only explained by aberrations 
induced by cumulating lenses in the trial frame. The correlation between the LDI and 
sphere was also reported by Brito et al. [5]. Furthermore, the correlation of LDI with CSDC 
confirmed that patients with a higher optical quality also had less LDI. This inverse rela-
tionship between contrast sensitivity and LDI was also reported by Escandón-García et al. 
[30]. LDI was also related with the increase of positive spherical aberration for a mesopic 
pupil size, which agrees with the results reported by Macedo-de-Araújo et al. [31].  
The average total score for the VF-14 questionnaire was 94.73, a value close to the 
mean score of 93.58 reported by Liu et al. [26]. Total spectacle independence was achieved 
at far and intermediate distance vision, but 19.4% of subjects reported the need for spec-
tacle use at a near distance, 6.5% reported this sometimes, and 12.9% seldom. The results 
of the current study were more optimistic than those reported by Mendicute et al. [2], and 
equal than those reported by Kohnen et al. [4] and Vargas et al. [32] for far and interme-
diate distance vision. However, these three studies reported slightly poorer levels of spec-
tacle independence at a near distance compared with the present study, with 10.8%, 12%, 
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and 10% of subjects, respectively, reporting the use of spectacles at near distances occa-
sionally. Considering all of the interviewed patients, high satisfaction rates were obtained, 
with more than 90% of them being satisfied or very satisfied at all distances, as previously 
reported by Liu et al. [26] (general satisfaction), but obtaining better results than that of 
Mendicute et al. [2] (>80% at intermediate and near) and poorer than those reported by 
Vargas et al. (100%) [32]. The high satisfaction rates explained that 88.9% of subjects would 
have taken the decision to be operated on again following the same procedure, close to 
the 92% rate reported by Kohnen et al. [4] and lower than the 98% rate reported by 
Mendicute et al. [2]  
No explants were conducted in any of the implanted eyes, but four (4.35%) subjects 
were excluded due to eye diseases that had developed in the course after surgery up to 
the 6 years of follow-up, and four subjects (4.35%) required corneal laser refractive retreat-
ment. This retreatment rate was lower than the 10.8% reported by Gundersen et al. [33] 
which is explained by the low residual astigmatism found in our sample, with all eyes 
with a residual astigmatism of 1.00 D or below. Indeed, these authors indicated that re-
sidual astigmatism was one of the main reasons for retreatment in their sample. The most 
frequent device-related ocular adverse event was PCO, which required Nd:YAG treat-
ment in 71.77% of the implanted eyes in a median time of 45 months. Bilbao-Calabuig et 
al. [10] reported a PCO rate with the 839MP IOL of 35% during 34 to 44 months. In the 
current series, the PCO rate for this same period of follow-up was slightly less than 30%. 
In any case, considering the higher increase in the slope of the survival plot after 40 
months in the current study, both studies would probably have converged in similar PCO 
rates at 6 years. The question has recently arisen whether Nd:YAG laser rate is expected 
to be risen in the future due to major affectation of mild PCO with MIOL than monofocal 
IOLs [34]. The results from our study were in agreement with this hypothesis, but efficacy 
and satisfaction were maintained in the long-term and no adverse events secondary to 
Nd:YAG laser were reported in any on the reviewed or interviewed patients. 
Our study has some limitations. Firstly, from the 92 patients implanted, 15 were not 
able to be contacted with the phone number retrieved in the clinical history; therefore the 
PROs did not contain a representation of all of the operated patients. A second limitation 
is related to assess Nd-YAG rates retrospectively or asking during the interview phone 
call, as the PCO grade could not be evaluated in the long term for these patients and some 
loss of information might have taken place. However, this was the reason we separately 
presented Nd-YAG rates for eyes attending the study visit and for those accounted 
through the clinical history or by phone, showing very similar lines in the survival plot. 
Finally, the cross-sectional study design led us to be cautious interpreting some findings, 
such as the possible reduction of light distortion with time. 
5. Conclusions 
In conclusion, this study reports the results for the longest follow-up time to date (6-
years) after the implantation of a trifocal intraocular lens (AT LISA tri 839MP). Efficacy 
was equal or better that the reported in previous literature at 12-months. PCO treatment 
with Nd:YAG capsulotomy was generally required, but no adverse events secondary to 
Nd:YAG treatment were found. PRO results in terms of little difficulties conducting daily 
tasks or high satisfaction rates were comparable to those reported in short term studies. 
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